Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Iterum Therapeutics plc Director's Dealing 2018

May 30, 2018

34796_dirs_2018-05-30_d53ef77e-2803-409a-8a41-124c05a0b72c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: Kelly David George (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-05-30 Ordinary Shares C 9548 Acquired 9548 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-05-30 Series A Preferred Shares $ C 9548 Disposed Ordinary Shares (9548) Direct

Footnotes

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: Not applicable.